The earnings call emphasized significant progress in clinical trials, a strong financial position, and positive market reception for their HCV program. However, challenges such as slower regulatory approvals outside North America and decreased interest income were noted. Despite these challenges, the overall sentiment is optimistic with a focus on future growth and market disruption.

Company Guidance

During the Atea Pharmaceuticals' Second Quarter 2025 Earnings Conference Call, the company provided comprehensive guidance on its ongoing initiatives and financial health. Atea highlighted significant progress in its global Phase III HCV program, which includes two trials, C-BEYOND in North America and C-FORWARD outside North America, with patient enrollment on track. Top-line results from C-BEYOND are expected by mid-2026, and C-FORWARD results by the end of 2026. The company reported a strong financial position with $379.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, and projected a cash runway extending through 2027. Additionally, Atea announced a $25 million stock repurchase plan and the addition of Dr. Howard Berman as a new independent director. The guidance emphasized Atea's commitment to enhancing shareholder value and advancing its HCV regimen, which could potentially become a best-in-class treatment in the $3 billion annual HCV market.

Progress in HCV Program

Atea Pharmaceuticals started dosing patients in their global Phase III development program for their HCV treatment, with a 98% cure rate demonstrated in Phase II trials.

Financial Position and Stock Repurchase

The company has $379.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, with a cash runway extending through 2027. Atea announced a repurchase of up to $25 million of the company’s common stock.

Market Research Insights

76% of high U.S. DAA prescribers are extremely likely to prescribe Atea's regimen, indicating strong market potential for their HCV treatment.

Appointment of New Independent Director

Dr. Howard Berman, with over 20 years of life science industry experience, was appointed as a new independent director.

Atea Pharmaceuticals (AVIR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AVIR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.41 / -	-0.37	―	―	―
Aug 07, 2025	2025 (Q2)	-0.41 / -0.44	-0.48	8.33% (+0.04)
May 12, 2025	2025 (Q1)	-0.50 / -0.40	-0.75	46.67% (+0.35)	―	―
Mar 06, 2025	2024 (Q4)	-0.29 / -0.40	-0.47	14.89% (+0.07)
Nov 07, 2024	2024 (Q3)	-0.43 / -0.37	-0.4	7.50% (+0.03)
Aug 07, 2024	2024 (Q2)	-0.66 / -0.48	-0.34	-41.18% (-0.14)
May 14, 2024	2024 (Q1)	-0.52 / -0.75	-0.43	-74.42% (-0.32)
Feb 28, 2024	2023 (Q4)	-0.43 / -0.47	-0.41	-14.63% (-0.06)
Nov 08, 2023	2023 (Q3)	-0.46 / -0.40	-0.1	-300.00% (-0.30)
Aug 08, 2023	2023 (Q2)	-0.47 / -0.34	-0.38	10.53% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AVIR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$3.46	$3.38	-2.31%
May 12, 2025	$2.96	$2.63	-11.15%
Mar 06, 2025	$3.00	$2.99	-0.33%
Nov 07, 2024	$3.44	$3.50	+1.74%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Atea Pharmaceuticals (AVIR) report earnings?

Atea Pharmaceuticals (AVIR) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Atea Pharmaceuticals (AVIR) earnings time?

Atea Pharmaceuticals (AVIR) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AVIR EPS forecast?

AVIR EPS forecast for the fiscal quarter 2025 (Q3) is -0.42.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing